4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $21,858,938 | -41.0% | 1,717,120 | -16.3% | 0.00% | -50.0% |
Q2 2023 | $37,051,270 | +5.5% | 2,050,430 | +0.4% | 0.00% | 0.0% |
Q1 2023 | $35,105,229 | -36.0% | 2,042,189 | -17.3% | 0.00% | 0.0% |
Q4 2022 | $54,865,718 | +907.8% | 2,470,316 | +264.8% | 0.00% | – |
Q3 2022 | $5,444,000 | +23.3% | 677,176 | +7.1% | 0.00% | – |
Q2 2022 | $4,415,000 | -80.4% | 632,525 | -57.5% | 0.00% | -100.0% |
Q1 2022 | $22,519,000 | -18.5% | 1,489,371 | +18.2% | 0.00% | 0.0% |
Q4 2021 | $27,637,000 | +220.6% | 1,259,660 | +294.1% | 0.00% | – |
Q3 2021 | $8,621,000 | +116.3% | 319,662 | +93.2% | 0.00% | – |
Q2 2021 | $3,985,000 | -14.0% | 165,492 | +54.9% | 0.00% | – |
Q1 2021 | $4,634,000 | – | 106,833 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |